First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

被引：0

作者：

Tripathy, Debu

Sohn, Joohyuk

Im, Seock-Ah

Colleoni, Marco

Franke, Fabio

Bardia, Aditya

Harbeck, Nadia

Hurvitz, Sara

Chow, Louis

Lee, Keun Seok

Campos-Gomez, Saul

Vazquez, Rafael Villanueva

Jung, Kyung Hae

Carlson, Gary

Hughes, Gareth

Diaz-Padilla, Ivan

Germa, Caroline

Hirawat, Samit

Lu, Yen-Shen

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea

[3] Seoul Natl Univ, Coll Med, Seoul, South Korea

[4] Ist Europeo Oncol, Unita Ric Senol Med, Milan, Italy

[5] CACONIjui, Hosp Caridade Ijui, Ijui, RS, Brazil

[6] Havard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[7] Univ Munich LMU, Breast Ctr, Munich, Germany

[8] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[9] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China

[10] Res Inst & Hosp, Natl Canc Ctr, Goyang, South Korea

[11] Inst Seguridad Social Estado Mexico & Municipios, Ctr Oncol Estatal, Toluca, Mexico

[12] Hosp Moises Broggi, Inst Catala Oncol, Barcelona, Spain

[13] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[14] Nova Pharmaceut Corp, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Natl Taiwan Univ Hosp, Taipei, Taiwan

来源：

CANCER RESEARCH | 2018年 / 78卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

GS2-05

引用

页数：1

共 50 条

[21] Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib plus letrozole vs placebo plus letrozole in the phase III MONALEESA-2 study
Blackwell, Kimberly L.
Paluch-Shimon, Shani
Campone, Mario
Conte, Pierfranco
Petrakova, Katarina
Favret, Anne
Blau, Sibel
Beck, J. Thaddeus
Miller, Michelle
Sutradhar, Santosh
Monaco, Mauricio
Burris, Howard A.
CANCER RESEARCH, 2018, 78 (04)
[22] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
Hortobagyi, G. N.
Stemmer, S. M.
Burris, H. A.
Yap, Y. S.
Sonke, G. S.
Paluch-Shimon, S.
Campone, M.
Blackwell, K.
Andre, F.
Winer, E. P.
Janni, W.
Verma, S.
Conte, P.
Arteaga, C. L.
Cameron, D.
Xuan, F.
Souami, F.
Miller, M.
Germa, C.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2016, 27
[23] First-line ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis
Tripathy, D.
Hortobagyi, G.
Chan, A.
Im, S-A
Chia, S.
Yardley, D.
Esteva, F. J.
Hurvitz, S.
Kong, O.
Bao, W.
Lorenc, K. Rodriguez
Diaz-Padilla, I.
Slamon, D. J.
CANCER RESEARCH, 2019, 79 (04)
[24] Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
Moy, Beverly
Neven, Patrick
Lebrun, Fabienne
Bellet, Meritxell
Xu, Binghe
Sarosiek, Tomasz
Chow, Louis
Goss, Paul
Zacharchuk, Charles
Leip, Eric
Turnbull, Kathleen
Bardy-Bouxin, Nathalie
Duvillie, Ladan
Lang, Istvan
ONCOLOGIST, 2014, 19 (04): : 348 - 349
[25] Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Binghe Xu
Qingyuan Zhang
Pin Zhang
Xichun Hu
Wei Li
Zhongsheng Tong
Tao Sun
Yuee Teng
Xinhong Wu
Quchang Ouyang
Xi Yan
Jing Cheng
Qiang Liu
Jifeng Feng
Xiaojia Wang
Yongmei Yin
Yanxia Shi
Yueyin Pan
Yongsheng Wang
Weimin Xie
Min Yan
Yunjiang Liu
Ping Yan
Fei Wu
Xiaoyu Zhu
Jianjun Zou
Nature Medicine, 2021, 27 : 1904 - 1909
[26] Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Xu, Binghe
Zhang, Qingyuan
Zhang, Pin
Hu, Xichun
Li, Wei
Tong, Zhongsheng
Sun, Tao
Teng, Yuee
Wu, Xinhong
Ouyang, Quchang
Yan, Xi
Cheng, Jing
Liu, Qiang
Feng, Jifeng
Wang, Xiaojia
Yin, Yongmei
Shi, Yanxia
Pan, Yueyin
Wang, Yongsheng
Xie, Weimin
Yan, Min
Liu, Yunjiang
Yan, Ping
Wu, Fei
Zhu, Xiaoyu
Zou, Jianjun
NATURE MEDICINE, 2021, 27 (11) : 1904 - +
[27] Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2,-3, and-7 trials
Beck, J. T.
Neven, P.
Esteva, F. J.
Bardia, A.
Harbeck, N.
Hurvitz, S.
O'Shaughnessy, J.
Verma, S.
Lanoue, B.
Alam, J.
Kong, O.
Chandiwana, D.
Chia, S.
CANCER RESEARCH, 2019, 79 (04)
[28] First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
Hortobagyi, Gabriel N.
Paluch-Shimon, Shani
Petrakova, Katarina
Villanueva, Cristian
Chan, Arlene
Nusch, Arnd
Yap, Yoon Sim
Hart, Lowell
Favret, Anne
Marschner, Norbert
Sonke, Gabe S.
Ohnstad, Hege Oma
Arteaga, Carlos
Su, Fei
He, Wei
Miller, Michelle Kristine
Stemmer, Salomon M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer
Wong, Vanessa
de Boer, Richard
Baron-Hay, Sally
Blum, Robert
Boyle, Frances
Chua, Susan
Clarke, Kerrie
Cuff, Katharine
Green, Michael
Lim, Elgene
Mok, Kelly
Nott, Louise
Nottage, Michelle
Tafreshi, Ali
Tsoi, Daphne
Uccellini, Anthony
Hong, Wei
Gibbs, Peter
Lok, Sheau Wen
CLINICAL BREAST CANCER, 2022, 22 (08) : 792 - 800
[30] Ribociclib plus endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials
Yardley, D. A.
Chan, A.
Nusch, A.
Sonke, G. S.
Yap, Y-S
Bachelot, T.
Esteva, F. J.
Slamon, D. J.
Burris, H. A.
Gaur, A.
Kong, O.
Diaz-Padilla, I.
Lorenc, K. Rodriguez
Wheatley-Price, P.
CANCER RESEARCH, 2019, 79 (04)

← 1 2 3 4 5 →